New cell-signaling pathways for controlling cytomegalovirus replication

S. Roy, Ravit Boger

Research output: Contribution to journalArticle

Abstract

Cytomegalovirus (CMV) is increasingly recognized as an accomplished modulator of cell-signaling pathways, both directly via interaction between viral and cellular proteins, and indirectly by activating metabolic/energy states of infected cells. Viral genes, as well as captured cellular genes, enable CMV to modify these pathways upon binding to cellular receptors, up until generation of virus progeny. Deregulation of cell-signaling pathways appears to be a well-developed tightly balanced virus strategy to achieve the desired consequences in each infected cell type. Importantly and perhaps surprisingly, identification of new signaling pathways in cancer cells positioned CMV as a sophisticated user and abuser of many such pathways, creating opportunities to develop novel therapeutic strategies for inhibiting CMV replication (in addition to standard of care CMV DNA polymerase inhibitors). Advances in genomics and proteomics allow the identification of CMV products interacting with the cellular machinery. Ultimately, clinical implementation of candidate drugs capable of disrupting the delicate balance between CMV and cell-signaling will depend on the specificity and selectivity index of newly identified targets. Modulation of cell-signaling pathways by cytomegalovirus is an important viral strategy for survival and infectivity, and mechanistic studies of these pathways may lead to the development of compounds with high selectivity against virus replication.

Original languageEnglish (US)
Pages (from-to)1249-1258
Number of pages10
JournalAmerican Journal of Transplantation
Volume14
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Cytomegalovirus
Viruses
Nucleic Acid Synthesis Inhibitors
Viral Genes
Viral Proteins
Standard of Care
Virus Replication
Genomics
Proteomics
Pharmaceutical Preparations
Genes
Neoplasms

Keywords

  • AMPK
  • ATM
  • CMV
  • mTOR
  • signal transduction
  • Wnt

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

New cell-signaling pathways for controlling cytomegalovirus replication. / Roy, S.; Boger, Ravit.

In: American Journal of Transplantation, Vol. 14, No. 6, 2014, p. 1249-1258.

Research output: Contribution to journalArticle

@article{a2f777dd56524297945923fe33bb6b9a,
title = "New cell-signaling pathways for controlling cytomegalovirus replication",
abstract = "Cytomegalovirus (CMV) is increasingly recognized as an accomplished modulator of cell-signaling pathways, both directly via interaction between viral and cellular proteins, and indirectly by activating metabolic/energy states of infected cells. Viral genes, as well as captured cellular genes, enable CMV to modify these pathways upon binding to cellular receptors, up until generation of virus progeny. Deregulation of cell-signaling pathways appears to be a well-developed tightly balanced virus strategy to achieve the desired consequences in each infected cell type. Importantly and perhaps surprisingly, identification of new signaling pathways in cancer cells positioned CMV as a sophisticated user and abuser of many such pathways, creating opportunities to develop novel therapeutic strategies for inhibiting CMV replication (in addition to standard of care CMV DNA polymerase inhibitors). Advances in genomics and proteomics allow the identification of CMV products interacting with the cellular machinery. Ultimately, clinical implementation of candidate drugs capable of disrupting the delicate balance between CMV and cell-signaling will depend on the specificity and selectivity index of newly identified targets. Modulation of cell-signaling pathways by cytomegalovirus is an important viral strategy for survival and infectivity, and mechanistic studies of these pathways may lead to the development of compounds with high selectivity against virus replication.",
keywords = "AMPK, ATM, CMV, mTOR, signal transduction, Wnt",
author = "S. Roy and Ravit Boger",
year = "2014",
doi = "10.1111/ajt.12725",
language = "English (US)",
volume = "14",
pages = "1249--1258",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - New cell-signaling pathways for controlling cytomegalovirus replication

AU - Roy, S.

AU - Boger, Ravit

PY - 2014

Y1 - 2014

N2 - Cytomegalovirus (CMV) is increasingly recognized as an accomplished modulator of cell-signaling pathways, both directly via interaction between viral and cellular proteins, and indirectly by activating metabolic/energy states of infected cells. Viral genes, as well as captured cellular genes, enable CMV to modify these pathways upon binding to cellular receptors, up until generation of virus progeny. Deregulation of cell-signaling pathways appears to be a well-developed tightly balanced virus strategy to achieve the desired consequences in each infected cell type. Importantly and perhaps surprisingly, identification of new signaling pathways in cancer cells positioned CMV as a sophisticated user and abuser of many such pathways, creating opportunities to develop novel therapeutic strategies for inhibiting CMV replication (in addition to standard of care CMV DNA polymerase inhibitors). Advances in genomics and proteomics allow the identification of CMV products interacting with the cellular machinery. Ultimately, clinical implementation of candidate drugs capable of disrupting the delicate balance between CMV and cell-signaling will depend on the specificity and selectivity index of newly identified targets. Modulation of cell-signaling pathways by cytomegalovirus is an important viral strategy for survival and infectivity, and mechanistic studies of these pathways may lead to the development of compounds with high selectivity against virus replication.

AB - Cytomegalovirus (CMV) is increasingly recognized as an accomplished modulator of cell-signaling pathways, both directly via interaction between viral and cellular proteins, and indirectly by activating metabolic/energy states of infected cells. Viral genes, as well as captured cellular genes, enable CMV to modify these pathways upon binding to cellular receptors, up until generation of virus progeny. Deregulation of cell-signaling pathways appears to be a well-developed tightly balanced virus strategy to achieve the desired consequences in each infected cell type. Importantly and perhaps surprisingly, identification of new signaling pathways in cancer cells positioned CMV as a sophisticated user and abuser of many such pathways, creating opportunities to develop novel therapeutic strategies for inhibiting CMV replication (in addition to standard of care CMV DNA polymerase inhibitors). Advances in genomics and proteomics allow the identification of CMV products interacting with the cellular machinery. Ultimately, clinical implementation of candidate drugs capable of disrupting the delicate balance between CMV and cell-signaling will depend on the specificity and selectivity index of newly identified targets. Modulation of cell-signaling pathways by cytomegalovirus is an important viral strategy for survival and infectivity, and mechanistic studies of these pathways may lead to the development of compounds with high selectivity against virus replication.

KW - AMPK

KW - ATM

KW - CMV

KW - mTOR

KW - signal transduction

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=84901363363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901363363&partnerID=8YFLogxK

U2 - 10.1111/ajt.12725

DO - 10.1111/ajt.12725

M3 - Article

C2 - 24839861

AN - SCOPUS:84901363363

VL - 14

SP - 1249

EP - 1258

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 6

ER -